Skip to main content
. 2014 Nov 4;5(22):11091–11102. doi: 10.18632/oncotarget.2691

Figure 2. Comparison of MALAT-1 score between positive and negative biopsies in the discovery and validation phases.

Figure 2

(A) Overall cohort in the discovery phase. (B) PSA 4-10 ng/ml cohort in the discovery phase. (C) Overall cohort in the validation phase. (D) PSA 4-10 ng/ml cohort in the validation phase.